Trials / Unknown
UnknownNCT05172037
Novaferon in Non-hospitalized Adult Patients With Mild COVID-19
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients With Mild COVID-19
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 222 (estimated)
- Sponsor
- Genova Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Novaferon | a novel recombinant antiviral protein drug |
| BIOLOGICAL | Placebo | Saline |
Timeline
- Start date
- 2021-10-28
- Primary completion
- 2022-03-01
- Completion
- 2022-06-01
- First posted
- 2021-12-29
- Last updated
- 2022-03-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05172037. Inclusion in this directory is not an endorsement.